Explore more
News
(Reuters) -GSK shares fell more than 6% on Friday to the bottom of Britain's blue-chip index after a U.S. FDA advisory panel ...
In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...
GSK PLC closed 19.70% below its 52-week high of £16.79, which the company achieved on September 9th.
The Swedish defense company posted better-than-expected earnings and [raised its annual sales guidance]( ...
The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...
With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...
GSK plc (NYSE:GSK) is one of the best cheap stocks under $50 to buy now. On July 15, BofA analyst Sachin Jain maintained a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback